<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358657</url>
  </required_header>
  <id_info>
    <org_study_id>2032.00</org_study_id>
    <secondary_id>NCI-2010-00192</secondary_id>
    <secondary_id>2032</secondary_id>
    <secondary_id>2032.00</secondary_id>
    <secondary_id>P01HL122173</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00358657</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders</brief_title>
  <official_title>HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects of fludarabine phosphate, cyclophosphamide and
      total-body irradiation followed by donor bone marrow transplant and cyclophosphamide,
      mycophenolate mofetil, tacrolimus, and sirolimus in treating patients with primary
      immunodeficiency disorders or noncancerous inherited disorders. Giving low doses of
      chemotherapy and total-body irradiation before a bone marrow transplant helps prepare the
      patient's body to accept the incoming donor's bone marrow and decrease the risk that the
      patient's immune system will reject the donor's stem cells. When the healthy stem cells from
      a donor are infused into the patient they may help the patient's bone marrow make stem cells,
      red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a
      donor can make an immune response against the body's normal cells called graft versus host
      disease. Giving cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus after the
      transplant may help decrease this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine safety of nonmyeloablative conditioning and hematopoietic cell transplantation
      (HCT) from human leukocyte antigen (HLA)-haploidentical related donors for patients with
      nonmalignant inherited disorders who do not have an HLA-matched related or unrelated donor.

      SECONDARY OBJECTIVES:

      I. Determine whether nonmyeloablative conditioning and HCT from an HLA-haploidentical related
      donor graft can establish mixed chimerism (&gt; 5% cluster of differentiation [CD]3+ donor
      T-cell chimerism) in patients with nonmalignant inherited disorders.

      II. Transplant related mortality at day 100.

      III. Incidence and severity of graft-versus-host disease (GHVD).

      IV. Immune reconstitution.

      V. Infections during the first 200 days after HCT.

      OUTLINE:

      NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously
      (IV) over 1 hour on days -6 to -2; cyclophosphamide IV over 1 hour on days -6 and -5; and
      undergo total body irradiation on day -1.

      TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant on day 0.

      POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on days 3
      and 4, and mycophenolate mofetil orally (PO) every 8 hours on days 5-30 then twice daily
      (BID) to day 40, and then if there is no evidence of active GVHD and donor engraftment is &gt;
      95% (or by principal investigator [PI] approval) taper until approximately day 96, or faster
      at discretion of PI. Patients also receive tacrolimus IV continuously over 22-24 hours
      starting on day 5 post-transplant and continue on tacrolimus through day 100 followed by a
      taper to approximately day 180 if there is no evidence of GVHD and their graft is doing well.
      Patients may convert to oral tacrolimus given BID or three times daily (TID) when the patient
      is able to take medications orally and has a therapeutic drug level. In addition, patients
      will receive sirolimus orally beginning on day 5 through day 180 followed by a taper to
      approximately day 210 if there is no evidence of GVHD and their graft is doing well.

      After completion of study treatment, patients are followed up at 6, 12, 18, and 24 months,
      and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2006</start_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft rejection/failure rate</measure>
    <time_frame>Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade III/IV acute GVHD preceding diagnosis of chronic GVHD</measure>
    <time_frame>By day 100</time_frame>
    <description>This will be deemed to occur if the lower level of a one-sided 80% confidence interval for either proportion exceeds 25% and will be evaluated after 5 patients have been followed. Adverse events will be assessed using an adapted version of the Common Toxicity Criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve greater than 5% donor T-cell chimerism</measure>
    <time_frame>By day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Immunodeficiency Syndrome</condition>
  <condition>Non-Cancer Diagnosis</condition>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplantation</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplantation</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplantation</other_name>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>AY 22989</other_name>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>Rapamycin</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo total-body irradiation</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary immunodeficiency disorder or other nonmalignant inherited disease (except
             Fanconi anemia) treatable by allogeneic HCT

          -  Patients with pre-existing medical conditions or other factors that renders them at
             high risk for regimen related toxicity or ineligible for conventional myeloablative
             HCT and who do not have HLA-matched related or unrelated donors

          -  Patients with a related donor who is identical for one HLA haplotype

          -  Acquired aplastic anemia: severe aplastic anemia (SAA) is defined as follows:

               -  Bone marrow cellularity &lt; 25%, or marrow cellularity &lt; 50% but with &lt; 30%
                  residual hematopoietic cells

               -  Two out of three of the following (in peripheral blood): neutrophils &lt; 0.5 x
                  10^9/L; platelets &lt; 20 x 10^9/L; reticulocytes &lt; 20 x 10^9/L

               -  SAA diagnostic criteria may be applied to assessment at initial diagnosis or
                  follow-up assessments

          -  DONOR: Related donors who are identical for one HLA haplotype

          -  DONOR: Bone marrow will be the only allowed stem cell source

        Exclusion Criteria:

          -  Fanconi anemia

          -  Suitably HLA-matched related or unrelated donors

          -  Patients with metabolic storage diseases who have severe central nervous system (CNS)
             involvement of disease, defined as intelligence quotient (IQ) score &lt; 70

          -  Cardiac ejection fraction &lt; 30% (or, if unable to obtain ejection fraction, shortening
             fraction &lt; 26%) on multiple-gated acquisition (MUGA) scan or cardiac echocardiogram
             (echo), symptomatic coronary artery disease, or other cardiac failure requiring
             therapy; patients with a history of, or current cardiac disease should be evaluated
             with appropriate cardiac studies and/or cardiology consult; patients with a shortening
             fraction of &lt; 26% must be seen by cardiology for approval

          -  Poorly controlled hypertension despite anti-hypertensive medications

          -  Patients with clinical or laboratory evidence of liver disease will need to be
             evaluated for the cause of the liver disease, its clinical severity in terms of liver
             function and the degree of portal hypertension; patients will be excluded if they are
             found to have fulminant liver failure, cirrhosis of the liver with evidence of portal
             hypertension, bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of
             bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic
             dysfunction evidenced by prolongation of the prothrombin time, ascites related to
             portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic
             viral hepatitis with total serum bilirubin &gt; 3 mg/dl, or symptomatic biliary disease

          -  Positive for human immunodeficiency virus (HIV)

          -  Females who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+]) or
             breast-feeding

          -  Fertile men or women who are unwilling to use contraceptives during HCT and up to 12
             months post-treatment

          -  Patients with fungal pneumonia with radiological progression after receipt of
             amphotericin formulation or mold-active azoles for greater than 1 month will not be
             eligible for this protocol

          -  DONOR: Donor-recipient pairs in which the HLA-mismatch is only in the
             host-versus-graft (HVG) direction; patients are homozygous and donor is heterozygous

          -  DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1
             x 10^8 nucleated cells/kg recipient ideal body weight)

          -  DONOR: HIV-positive donors

          -  DONOR: A positive anti-donor cytotoxic cross match is absolute donor exclusion

          -  DONOR: &lt; 6 months old and &gt; 75 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Burroughs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital at TriStar Centennial</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haydar A. Frangoul</last_name>
      <phone>615-329-7339</phone>
      <email>Haydar.Frangoul@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Haydar A. Frangoul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Connelly</last_name>
      <phone>615-936-1762</phone>
      <email>james.a.connelly@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>James Connelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri M. Burroughs</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Lauri M. Burroughs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

